Ray Therapeutics, Inc.

Ray Therapeutics, Inc.

Biotechnology Research

San Francisco, California 3,304 followers

Optogenetic Gene Therapy Company

About us

Ray Therapeutics Inc (RayTx) is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting (and will not require light-enhancing goggles). Our studies have shown for the first time that our proprietary ChRown optogenetic protein can restore high levels of visual acuity, contrast sensitivity and visual field. RayTx lead asset, RTx-015, is expected to address the huge unmet medical in people suffering from many forms of retinal blindness (independent of the underlying genetic cause), including those with advanced age-related macular degeneration. RayTx has partnered with a world-leading AAV gene therapy manufacturer is utilizing their proprietary commercial manufacturing process and analytics to maximally de-risk clinical development. RayTx anticipates clinical trials will begin by the end of 2023 in our initial indication, retinitis pigmentosa.

Website
http://www.raytherapeutics.com
Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
San Francisco, California
Type
Privately Held
Founded
2021

Locations

Employees at Ray Therapeutics, Inc.

Updates

Similar pages

Browse jobs

Funding